Targeted Therapies for Metastatic Melanoma

Sunandana Chandra, Anna C. Pavlick*

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.

Original languageEnglish (US)
Pages (from-to)517-524
Number of pages8
JournalDermatologic clinics
Volume30
Issue number3
DOIs
StatePublished - Jul 1 2012

Fingerprint

Melanoma
Standard of Care
Therapeutics
Survival
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Immunotherapy
  • Metastatic melanoma
  • Signaling pathways
  • Targeted therapies

ASJC Scopus subject areas

  • Dermatology

Cite this

Chandra, Sunandana ; Pavlick, Anna C. / Targeted Therapies for Metastatic Melanoma. In: Dermatologic clinics. 2012 ; Vol. 30, No. 3. pp. 517-524.
@article{aa3e46cc108a447c8238d4b79d07d71f,
title = "Targeted Therapies for Metastatic Melanoma",
abstract = "The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.",
keywords = "Immunotherapy, Metastatic melanoma, Signaling pathways, Targeted therapies",
author = "Sunandana Chandra and Pavlick, {Anna C.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.det.2012.05.001",
language = "English (US)",
volume = "30",
pages = "517--524",
journal = "Dermatologic Clinics",
issn = "0733-8635",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Targeted Therapies for Metastatic Melanoma. / Chandra, Sunandana; Pavlick, Anna C.

In: Dermatologic clinics, Vol. 30, No. 3, 01.07.2012, p. 517-524.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeted Therapies for Metastatic Melanoma

AU - Chandra, Sunandana

AU - Pavlick, Anna C.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.

AB - The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.

KW - Immunotherapy

KW - Metastatic melanoma

KW - Signaling pathways

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84863865785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863865785&partnerID=8YFLogxK

U2 - 10.1016/j.det.2012.05.001

DO - 10.1016/j.det.2012.05.001

M3 - Review article

C2 - 22800555

AN - SCOPUS:84863865785

VL - 30

SP - 517

EP - 524

JO - Dermatologic Clinics

JF - Dermatologic Clinics

SN - 0733-8635

IS - 3

ER -